Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

Shahida Bibi with her familyTwo years ago, I started experiencing severe headaches and stomach pain, followed by abnormal ...

Camrelizumab/famitinib combination significantly improved PFS and OS over platinum-based chemotherapy in recurrent/metastatic ...

The FDA approved the first at-home cervical cancer screening in May. Texas is the eighth state to have access to the test as ...